Stent Placement — Cost, Top Hospitals & Success Rates | MyMedicPlus

Stent placement is an interventional procedure in which a tubular metallic or plastic endoprosthesis is deployed within a narrowed or obstructed tubular body structure — vessel, duct, or organ — to maintain patency and restore flow or drainage. Stents can be deployed via endovascular approach (vascular stenting — coronary, peripheral, renal, carotid arteries; venous stenting — SVC, iliac, portal veins), endoscopic approach (biliary and pancreatic duct stenting via ERCP; esophageal, colonic, duodenal stenting via endoscopy), percutaneous approach (percutaneous transhepatic biliary stenting — PTBD; nephrostomy with ureteral stenting; tracheobronchial stenting under bronchoscopy), or fluoroscopic approach (vascular stenting as part of angioplasty, TIPS stenting in portal hypertension). Stent types: self-expanding metallic stents (SEMS — permanent or removable; uncovered allowing tissue ingrowth, or covered to prevent ingrowth — better for benign strictures and when removal may be needed); balloon-expandable metallic stents (coronary DES, biliary); plastic stents (removable, for temporary biliary/pancreatic decompression); drug-eluting stents (antiproliferative coating in coronary/peripheral arteries); biodegradable stents (esophageal, biliary — experimental). Stent patency depends on stent type, location, underlying disease, and tumor ingrowth/overgrowth — typically 4-12 months for malignant biliary obstruction, 2-5 years for benign biliary stricture, lifelong for vascular stents with adequate antiplatelet therapy.

Stent placement addresses obstructive pathology across multiple organ systems. Biliary stenting: malignant biliary obstruction — cholangiocarcinoma, pancreatic head carcinoma, hepatocellular carcinoma involving bile duct, gallbladder carcinoma, metastatic lymph node compression; palliative stenting restores bile drainage in 90-95%; self-expanding metallic biliary stents (SEMS) patent for median 4-8 months vs plastic stents 2-3 months; benign biliary stricture — primary sclerosing cholangitis, anastomotic biliary stricture post-liver transplant, post-cholecystectomy bile duct injury; sequential plastic stents or fully-covered SEMS (fcSEMS) facilitate stricture dilation over 12-24 months. Esophageal stenting: malignant esophageal obstruction (squamous cell carcinoma, adenocarcinoma) for dysphagia palliation; esophago-respiratory fistula (anti-reflux SEMS seals fistula); corrosive stricture; anastomotic leak (covered SEMS as bridge to healing). Colorectal stenting: malignant colonic obstruction as bridge to elective surgery or for palliative decompression — avoids emergency colostomy in 80%. Ureteral stenting: ureteral obstruction from pelvic malignancy (cervical, bladder, prostate cancer), retroperitoneal fibrosis, anastomotic stricture after renal transplant, ureteral calculus (temporary decompression); metallic ureteral stents offer 6-12 months patency vs plastic 3-6 months. Vascular stenting: see Angioplasty and Angiography guides for coronary/peripheral arterial stenting. SVC syndrome from malignant compression: SEMS achieves symptomatic relief in 90% within 24-48 hours; tracheobronchial stenting for central airway obstruction or malignant stricture. Portal vein stenting in TIPS for portal hypertension.

Eligibility for stent placement varies by indication. Biliary stenting eligibility: confirmed biliary obstruction on cross-sectional imaging (CT/MRI/MRCP); liver function assessment (bilirubin level, LFTs); coagulation profile (INR <1.5 for PTBD approach); assessment of bile duct anatomy (stricture level — Bismuth classification for hilar cholangiocarcinoma — determines whether ERCP or PTBD approach is optimal). ERCP is preferred for distal biliary obstruction (pancreatic head, distal CBD); PTBD via percutaneous transhepatic approach preferred for proximal/hilar obstruction or failed ERCP. Curative vs palliative intent determines stent type: metal stents for palliation, plastic stents as bridge to surgery (metal stents may complicate surgical margins). For malignant colorectal obstruction: confirmed complete or near-complete obstruction on CT enema or colonoscopy; adequate cardiac fitness for endoscopy; decision on surgical vs palliative intent (STAG trial — bridge to surgery vs emergency surgery — mixed results). Ureteral stent eligibility: confirmed ureteral obstruction causing hydronephrosis or renal impairment; patient preference vs nephrostomy tube (stent avoids external collection bag but requires exchange every 3-6 months). SVC stent eligibility: confirmed SVC obstruction on CT venography, clinical syndrome (facial edema, arm swelling, cyanosis, dyspnea), biopsy to confirm malignancy where feasible. Contraindications to stent placement: uncorrectable coagulopathy, inaccessible target, patient unable to cooperate with procedure.

Stent Placement employs image-guided minimally invasive techniques performed in a dedicated catheterization laboratory or interventional radiology suite under fluoroscopy, ultrasound, CT, or biplane DSA guidance. Patient preparation: fasting 4–6 hours, IV access, baseline coagulation profile (INR <1.5, platelets >50,000 for most procedures), renal function (pre-hydration if eGFR <45 and contrast anticipated), pre-procedure antiplatelet loading (aspirin 300 mg + clopidogrel 300 mg loading for coronary procedures). Access: femoral artery (4–6 French sheath, right groin — standard for most procedures) or radial artery (5–6 French — preferred for coronary procedures; immediate ambulation; lower bleeding complications). Seldinger technique: percutaneous puncture → guidewire → introducer sheath → diagnostic catheter → exchange for working catheter and devices. Contrast-enhanced roadmap angiography defines the target anatomy before intervention. Device selection depends on lesion characteristics: drug-eluting stents (DES) for coronary restenosis prevention; self-expanding metallic stents (NITINOL) for venous and biliary applications; balloon-expandable stents for precise deployment at ostial lesions; drug-coated balloons (DCB) for below-the-knee and in-stent restenosis. Haemostasis post-procedure: manual pressure 10–15 minutes for femoral access; radial compression band for 3–4 hours; closure device (Angioseal, Perclose) for larger sheaths. Antiplatelet therapy (aspirin + P2Y12 inhibitor) prescribed for 1–12 months post-stent based on indication. Patient and family education about treatment goals, expected timeline, and self-management strategies is integrated throughout treatment delivery, supporting adherence and optimising long-term outcomes.

Biliary SEMS placement: technical success >95% for distal biliary obstruction via ERCP; clinical success (bilirubin reduction >50% within 2 weeks) in 85-90%; median patency 4-8 months uncovered SEMS, 6-12 months covered SEMS; plastic stents require reintervention every 3 months (3-month patency in 85%); SEMS superior to plastic for survival in patients with life expectancy >3-6 months. Esophageal SEMS for malignant dysphagia: immediate improvement in dysphagia score in 85-90% of patients (dysphagia score 0-4, from near-complete to semi-solid diet); procedure-related mortality <1% in experienced hands; median stent patency 6-9 months; significantly better quality of life vs no treatment for incurable esophageal cancer. Colonic SEMS as bridge to surgery: avoids emergency colostomy in 80%; allows bowel preparation and elective resection with primary anastomosis (avoids 2-stage surgery); STAG trial showed comparable 5-year oncological outcomes to emergency surgery for non-perforated malignant obstruction. Ureteral metallic stents: superior to plastic stents (6-12 month patency vs 3-6 months) in malignant ureteral obstruction; avoids repeated exchange under anesthesia; improve renal function and allow chemotherapy continuation in oncology patients. SVC stent (SEMS): rapid symptom relief in 90% within 24-48 hours (swelling, dyspnea, headache dramatically improved); durable patency 6-12 months; most cost-effective palliation for SVC syndrome. Tracheobronchial stent for malignant central airway obstruction: immediate dyspnea relief in 70-80%; allows continuation of radiation/chemotherapy; silicone stents removable via rigid bronchoscopy.

Biliary stent complications: pancreatitis post-ERCP (2-5% for diagnostic, 3-8% for sphincterotomy — prophylactic rectal indomethacin reduces risk by 50-60%); cholangitis (1-5%); biliary perforation (<1%); stent migration (covered SEMS 5-10%, plastic stents 2-5%); stent occlusion — tumor ingrowth (uncovered SEMS 20-30% at 6 months), tumor overgrowth, sludge (covered SEMS); hemorrhage from sphincterotomy or PTBD access (0.5-1%). Esophageal stent complications: chest pain and discomfort (50-70% — often requiring analgesics for 1-2 weeks); stent migration (10-20% — risk increased with covered stents and esophago-gastric junction stents); tumor overgrowth/ingrowth (15-25%); bleeding (2-5%); esophageal perforation (1-2%); aspiration — anti-reflux stent designs recommended for cardia stents; food bolus impaction (10-15%); stent erosion through vessel wall (rare, life-threatening aorto-esophageal fistula). Colonic stent complications: perforation (3-12% — higher risk with dilation and in lower rectum/sigmoid, also higher with bevacizumab use — avoid colonic stenting in antiangiogenic therapy); migration (5-10%); obstruction from tumor ingrowth (10-15% at 3 months); re-obstruction. Renal and ureteral stent complications: stent-related urinary symptoms (urgency, frequency, hematuria — 'stent syndrome' in 30-80%); encrustation (months of dwell time without exchange); stent fracture (metallic — rare); infection; stent migration. SVC stent: SVC re-thrombosis (5-10%); pulmonary embolism (2-3%); cardiac arrhythmia (stent entry into right atrium); bleeding from anticoagulation (mandatory with stenting in thrombotic SVC syndrome). Antiplatelet requirements for vascular stents (see Angioplasty guide).

Post-procedure monitoring for Stent Placement begins immediately after the procedure. Vital signs every 30 minutes for 2 hours, then hourly for 4–6 hours; access site assessment for haematoma, active bleeding, or pseudoaneurysm formation; serum creatinine at 24–48 hours post-contrast in patients with CKD or diabetes. Pain management with oral analgesics; adequate hydration to prevent contrast nephropathy (1,000 mL normal saline post-procedure). Short-term follow-up (1–4 weeks): clinical assessment of symptom response; duplex ultrasound or CT imaging to confirm target patency and technical success; antiplatelet therapy adherence review. Long-term surveillance (3–6–12 months): imaging surveillance for restenosis or reocclusion — timing determined by procedure type; clinical reassessment; further intervention planned early if restenosis identified before progression to total occlusion (re-intervention easier and more successful on residual stenosis than reocclusion).

Interventional radiology procedure costs for Stent Placement vary by device complexity, imaging guidance, and healthcare system. India offers 75–90% cost savings vs the USA. Basic IR procedures (angiography, image-guided biopsy): $500–2,000 India vs $5,000–20,000 USA. Intermediate procedures (embolization, ablation, complex stenting): $1,500–8,000 India vs $15,000–50,000 USA. Imported devices (stents, coils, ablation probes) are 40–70% cheaper in India due to volume-based pricing. Catheterization laboratory charges: $500–2,000/session India vs $5,000–15,000/session USA. Post-procedure imaging surveillance (duplex ultrasound, CTA): $100–400 India vs $1,000–5,000 USA per study. India's leading IR centers (AIIMS, Apollo, Fortis Escorts, Narayana, Medanta, SGPGI) perform high volumes of complex procedures with outcomes matching international benchmarks, making them premier medical tourism destinations for vascular and interventional procedures. Patients should request itemized all-inclusive quotes from multiple accredited facilities to enable informed cost comparisons before committing to a treatment centre.

Open surgical repair is the primary alternative to minimally invasive Stent Placement: bypass grafting, open resection, or conventional surgery offers durable outcomes for complex anatomical configurations but with substantially greater morbidity, longer hospital stays (5–10 days vs 1–2 days), and longer recovery (4–6 weeks vs 1–2 weeks). Endoscopic alternatives (ERCP, colonoscopy, bronchoscopy) are relevant for luminal interventions — choice depends on lesion location and access anatomy. Medical management alone (pharmacological risk factor control) is appropriate for asymptomatic or mildly symptomatic lesions where intervention risk exceeds benefit — validated by ISCHEMIA trial data for stable coronary disease and COURAGE trial evidence. Watchful waiting with serial surveillance imaging is reasonable for slowly progressive or anatomically benign lesions. Hybrid procedures combining open surgical exposure with endovascular techniques address complex anatomy not suitable for either approach alone.